Cytiva has completed major expansions at production sites across the US, Europe, and Asia to bolster its chromatography resins and filtration product manufacturing. This $1.6 billion investment since 2019 supports speedier customer deliveries, enhanced automation, and new manufacturing lines, reflecting growing demand in biopharmaceutical production. These capacity increases strengthen Cytiva’s in-region, for-region strategy and readiness for advanced therapeutics development.